Peripheral Autonomic Block (BAP) Plus Transversus Abdominis Plane Block (TAP) for Postoperative Analgesia After Minimally Invasive Left-Sided Colorectal Resection (BAPTAP): A Randomized, Controlled, Double-Blind Trial
Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Effective postoperative pain management is essential for enhanced recovery after laparoscopic colorectal surgery. This randomized, controlled, double-blind trial will compare conventional postoperative analgesia (intravenous medications plus surgical wound infiltration) with a locoregional strategy combining a peripheral autonomic block (inferior mesenteric and superior hypogastric plexuses) and a transversus abdominis plane (TAP) block. We hypothesize that the combined strategy (BAPTAP) reduces pain intensity and opioid consumption in the first 48 hours after Left-Sided Colorectal Resection.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Elective laparoscopic left-sided colorectal resection
• ASA physical status I-II
• Ability to understand the study and sign informed consent
Locations
Other Locations
Brazil
Santa Casa de Misericórdia de Belo Horizonte
RECRUITING
Belo Horizonte
Contact Information
Primary
MATHEUS MMMDE MEYER, MD
matheusww@gmail.com
5531988044987
Time Frame
Start Date: 2026-02-12
Estimated Completion Date: 2027-07-05
Participants
Target number of participants: 140
Treatments
Experimental: Arm A - Experimental: BAPTAP (Peripheral Autonomic Block + TAP Block)
General anesthesia and Peripheral autonomic plexus block (superior hypogastric and inferior mesenteric plexuses) with ropivacaine 0.2%, 8 mL per site; performed laparoscopically prior to dissection, associated with Bilateral ultrasound-guided TAP block using ropivacaine 0.33%, 30 mL per side.
Active_comparator: Arm B - Control: Trocar/wound infiltration (Standard of Care)
General anesthesia and trocar/wound infiltration - ropivacaine 0.33% up to 60 mL total.
Related Therapeutic Areas
Sponsors
Leads: Faculdade de Ciências Médicas de Minas Gerais
Collaborators: Santa Casa de Misericórdia de Belo Horizonte